Core Viewpoint - Rosen Law Firm is urging investors of Cytokinetics, Inc. to take action before the November 17, 2025 deadline related to a securities class action lawsuit concerning misleading statements about the company's New Drug Application for aficamten [2][6]. Group 1: Class Action Details - The class action pertains to investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025, and may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [4][6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of significant settlements, including over $438 million secured for investors in 2019, and has been recognized for its success in securities class action settlements [5]. Group 3: Case Allegations - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [6]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to investor damages when the true information was revealed [6].

New York, New York--(Newsfile Corp. - November 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hormel Foods Corporation (NYSE: HRL) resulting from allegations that Hormel may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Hormel securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zions Bancorporation due to allegations of materially misleading business information issued to the public [1] Group 1: Legal Action and Investor Rights - Investors who purchased Zions Bancorporation securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Financial Impact and Company Disclosure - On October 15, 2025, Zions Bancorporation announced a $50 million charge-off related to a loan from its subsidiary, California Bank & Trust, due to misrepresentations and contractual defaults [3] - Following this announcement, Zions Bancorporation's common stock experienced a decline of 13.14% on October 16, 2025 [4] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [5] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Legal Action - Shareholders of Firefly Aerospace who purchased securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Financial Performance - Firefly Aerospace reported a wider loss and lower revenue in its latest quarter, marking its first earnings report since its stock market debut [3]. - Following the negative earnings report, Firefly's stock fell by 15.3% on September 23, 2025 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar in 2020 [4].

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D ...

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit claims that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5]. Group 3: Next Steps for Investors - To join the class action, investors can visit the provided link or contact the law firm directly for more information [4][7]. - It is noted that no class has been certified yet, and investors are not represented unless they retain counsel [8].

New York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hormel Foods Corporation (NYSE: HRL) resulting from allegations that Hormel may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Hormel securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the “Class Period”), of the important December 29, 2025 lead plaintiff deadline. SO WHAT: If you purchased Avantor common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1] Group 1: Class Action Details - Investors who purchased or sold Cepton common stock between July 29, 2024, and January 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, interested parties can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at that time and has consistently ranked highly in securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations during the Class Period [5] - Specific allegations include the failure to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition and the Board's failure to explore this offer meaningfully [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific claims include that Baxter was aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5]. - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].